PTD-DBM is a peptide that disrupts the interaction between Dishevelled (Dvl) and β-catenin in the Wnt signaling pathway. Research focuses on hair follicle regeneration and androgenetic alopecia.
Standard Research Dosage
Topical application: 1–3% concentration in carrier solution, applied to scalp 1–2x daily. Intradermal injection: 0.1–0.5 mg per session, 1x per week. Topical application is the primary research route for hair loss applications.
Wnt Signaling Mechanism
PTD-DBM penetrates cell membranes (via the PTD domain) and inhibits the Dvl-β-catenin interaction, activating Wnt/β-catenin signaling in dermal papilla cells. This promotes hair follicle cycling from telogen (resting) to anagen (growth) phase.
Research Evidence
A 2017 study in Science Advances showed PTD-DBM promoted hair regeneration in mouse models of alopecia. Human clinical data is limited but promising for androgenetic alopecia applications.